Aurum Equity Partners LLP is delighted to introduce
our quarterly newsletter‚ which will provide updates‚
insights and perspectives on the pharmaceutical
sector in India.
Click here to download the Newsletter
We believe you will find the information useful and relevant.
Do let us know if you would like to share your insights and perspectives‚ we would attempt to incorporate them in our future Newsletters.
If you have any suggestions on what we could
include‚ please write to me or to our Knowledge
Services team at firstname.lastname@example.org.
Founder– Aurum Equity Partners LLP
|In this issue
- The prospects of the Global generics
market are looking bright over the next
few years‚ given the pro–generic
environment in developed markets‚
rising utilization levels‚ patent expiries
and growing Government role in
providing healthcare in emerging
- The overseas markets represent a
large opportunity and many Indian
companies like Sun‚ Lupin‚ Cipla‚
Zydus‚ Torrent have been expanding
their presence over the past few years
- The recent deals over the past 6–12
months does indicate Indian Pharma
companies’ aggressive plans to build a
global pharma franchise and we expect
many more Indian companies to
emerge as global leaders in the fast
growing generic market